Arcellx Inc

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

Gilead Extends Tender Offer to Acquire Arcellx

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings